Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
AORT disclosed a Form 144 notice for a proposed sale of 34,210 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value $1,568,812.44. The filing lists an approximate sale date of 11/13/2025 on the NYSE.
The shares derive from recent restricted stock vesting: 17,105 shares on 11/10/2025 and 17,105 shares on 11/11/2025, each marked as Compensation. A recent activity section shows sales in the last three months by James Mackin of 12,500 shares on 08/15/2025 for $528,991.00 and 17,580 shares on 11/11/2025 for $784,400.26. Shares outstanding were 47,374,939 at the time referenced in the filing.
AORT filed a Form 144 for a proposed sale of up to 4,993 common shares, with an aggregate market value of $228,970.50. The approximate sale date is 11/13/2025, through Fidelity Brokerage Services LLC, on the NYSE.
The shares were acquired via restricted stock vesting as compensation: 2,496 shares on 11/10/2025 and 2,497 shares on 11/11/2025. In the past three months, the seller reported sales of 18,200 shares on 08/27/2025 for $801,211.32 and 2,566 shares on 11/11/2025 for $114,492.10. Shares outstanding were 47,374,939; this is a baseline figure, not the amount being offered.
John E. Davis filed a Form 144 notice to sell up to 6,563 shares of common stock, with an aggregate market value of $300,968.02. The shares are slated for sale on or after 11/13/2025 on the NYSE through Fidelity Brokerage Services LLC.
The securities were acquired via restricted stock vesting from the issuer on 11/10/2025 (3,282 shares) and 11/11/2025 (3,281 shares), recorded as compensation. The filing also lists a recent sale by the same person on 11/11/2025 of 3,373 shares for gross proceeds of $150,499.55. Shares outstanding were 47,374,939; this is a baseline figure, not the amount being sold.
Artivion (AORT): Schedule 13G/A Amendment No. 6—Macquarie Group Limited and affiliates reported beneficial ownership of 2,483,842 Artivion common shares, representing 5.26% of the class as of September 30, 2025. Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust report sole voting and dispositive power over 2,483,842 shares. The certification states the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Artivion (AORT) insider activity: The company’s SVP and General Counsel reported multiple transactions. On 11/10/2025, 2,960 shares of common stock were sold at $44.619 to cover tax withholding upon RSU vesting. On 11/11/2025, the insider exercised 10,000 stock options at an exercise price of $11.03 (code M) and sold 10,000 shares at $46.18. Following these transactions, the insider directly held 169,169 common shares.
The option exercised was originally granted with vesting at 33 1/3% per year beginning on 11/08/2023 and had an expiration date of 11/08/2029.
Artivion (AORT) reported an insider transaction by President & CEO James P. Mackin.
On 11/10/2025, 17,580 shares of common stock were sold at $44.619 in a sell-to-cover tied to RSU vesting to satisfy tax withholding; the filing states this was not a discretionary trade.
After the transaction, he directly beneficially owned 835,203 shares.
Artivion, Inc. (AORT) reported an insider transaction. Chief Commercial Officer John E. Davis disclosed the sale of 3,373 shares of common stock on 11/10/2025 at $44.619 per share.
The filing states the shares were sold upon RSU vesting to cover tax withholding obligations via a sell-to-cover and “does not represent a discretionary transaction.” Following the transaction, Davis directly beneficially owned 205,405 shares.
Artivion, Inc. (AORT) insider transaction: the VP, Chief Accounting Officer reported a sale of 1,789 shares of common stock on 11/10/2025 at $44.619 per share. Following the transaction, the reporting person beneficially owns 144,862 shares, held directly.
The filing states the shares were sold to cover taxes due upon the vesting of restricted stock units, described as a “sell to cover” and not a discretionary trade.
Artivion, Inc. (AORT) disclosed an insider transaction by its SVP, Clinical & MD Affairs. On 11/10/2025, the officer sold 2,566 shares of common stock at $44.619 per share. The filing states the shares were sold upon the vesting of restricted stock units to cover tax withholding, described as a “sell to cover” and not a discretionary trade.
Following the transaction, the officer directly beneficially owned 61,634 shares. The report was filed as a single‑person Form 4 submission.
AORT received a Rule 144 notice for a proposed sale of 2,566 common shares through Fidelity Brokerage Services, with an aggregate market value of $114,492.10. The approximate sale date is 11/11/2025 on the NYSE.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer as compensation. A separate table shows a sale of 18,200 shares on 08/27/2025 by Marshall S. Stanton, for $801,211.32 in gross proceeds. Shares outstanding were 47,374,939.